

# Tranexamic Acid Oral (LYSTEDA)

## Criteria For Use

### March 2023

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

### Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive oral tranexamic acid.

- Hypersensitivity
- Concomitant use of combined hormonal contraceptives\*
- History of or active thromboembolic disease or intrinsic risk of thrombosis or thromboembolism, including retinal vein or artery occlusion

\*Contraindicated per U.S. product label. Concern for increased risk of venous or arterial thromboembolism based on pharmacodynamics and U.S. postmarketing events, particularly in patients who are obese or cigarette smokers. No clinical trial data are available, as patients on concomitant combination hormonal contraceptives were excluded.

---

Prepared: March 2023. Contact: Lisa Longo, Pharm.D., BCPS, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)

---